Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People's Republic of China. The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant intensive, first line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma indications. It is also involved in the development of Utidelone antibody drug conjugate in preclinical studies; and BG22, BG18, and BG44 products for solid tumor indications in preclinical studies. Beijing Biostar Pharmaceuticals Co., Ltd. was incorporated in 2002 and is headquartered in Beijing, China.
Frequently asked questions
What sector does Beijing Biostar Pharms Co Ltd (2563) operate in?
Beijing Biostar Pharms Co Ltd belongs to the Other sector and operates in the Biotechnology industry.
What is Beijing Biostar Pharms Co Ltd (2563) current stock price?
As of the latest data, Beijing Biostar Pharms Co Ltd stock price is HK$3.79, with a previous close of HK$3.80. Beijing Biostar Pharms Co Ltd lost -HK$0.01 in the last trading session, representing a -0.26% loss.
What is Beijing Biostar Pharms Co Ltd (2563) current market capitalization?
Beijing Biostar Pharms Co Ltd market cap is approximately 916.12 million.
What is Beijing Biostar Pharms Co Ltd (2563) EBITDA?
Beijing Biostar Pharms Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.78 million.
Does Beijing Biostar Pharms Co Ltd (2563) pay dividends?
No. Beijing Biostar Pharms Co Ltd does not pay a dividend.
What is Beijing Biostar Pharms Co Ltd (2563) beta (volatility) score?
Beijing Biostar Pharms Co Ltd has a beta of 0.827, meaning its volatility is roughly in line with the market.
